Question

In the Phase 3 COMET trials, which outcome best reflects the clinical benefit of acoltremon in patients with DED?
A. No difference from vehicle in Schirmer scores through 90 days
B. Significant tear production increases within 14 days, sustained through 90 days
C. Improvements in ocular redness, with no impact on patient-reported outcomes
D. Rapid tear production improvement requiring concurrent corticosteroid therapy

Answer 1

B

In the Phase 3 COMET trials acoltremon produced significant increases in tear production detectable by about 14 days and those improvements were sustained through 90 days, reflecting a rapid and durable clinical benefit for patients with DED.